Weekly Docetaxel/Irinotecan for Non-resectable Gastric Cancers After Cisplatin Plus 5-FU/Leucovorin

Sponsor
National Taiwan University Hospital
Study ID
NCT00166881
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
16 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

In this study, the investigators will use P-HDFL, a regimen with high tumor remission rate (\~ 60-70%) and with only modest treatment-associated toxicities, as induction chemotherapy for patients with non-resectable gastric cancer. For those patients who have achieved complete response (CR) or partial response (PR), DI will be used to "consolidate" the remission. For those patients who fail to achieve remission by P-HDFL, DI will be used as salvage chemotherapy. The efficacy and toxicities of DI in these two settings will be evaluated in this prospective study.

Key Dates

Start date
Jun 30, 2000
Status verified
Nov 2012
Primary completion
Dec 31, 2010
Completion
Jun 30, 2011

Study Design

Enrollment
29 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: A, 2, III
    Weekly Docetaxel-Irinotecan for Inoperable Gastric Cancers After P-HDFL

Primary Outcome Measure

Overall survival (OS) [ Time Frame: Five years ]

Related Studies